News &amp; Updates

Asian patients with moderate to severe plaque psoriasis may benefit from ustekinumab therapy, which has been shown to be both safe and effective in a Singapore study.

Ustekinumab safe, effective in Asians with moderate to severe plaque psoriasis

14 Jul 2023

Higher SUA to creatinine ratio ups risk of pre-eclampsia, adverse pregnancy outcomes

During pregnancy, a higher serum uric acid (SUA) to creatinine (sCr) ratio appears to elevate the risk of pre-eclampsia (PE) and adverse pregnancy outcomes, suggests a recent study.

Higher SUA to creatinine ratio ups risk of pre-eclampsia, adverse pregnancy outcomes

Fitusiran cuts bleeding in haemophilia patients regardless of inhibitor use

In the phase III ATLAS-PPX trial, the investigational siRNA* therapeutic fitusiran significantly cut bleeding events compared with factor/bypassing agent (BPA) prophylaxis in patients with haemophilia A or B with or without inhibitors.

Fitusiran cuts bleeding in haemophilia patients regardless of inhibitor use

Amblyopia protective against age-related macular degeneration

Less amblyopic individuals are more likely to have age-related macular degeneratio n (AMD) diagnosed on the amblyopic eye than on the nonamblyopic eye, as reported in a study. Meanwhile, individuals with lateral asymmetry tend to have the more advanced form of AMD on the nonamblyopic eye.

Amblyopia protective against age-related macular degeneration

14 Jul 2023

On April 15, 2023, ZP Therapeutics held a scientific symposium entitled Taking Hope Further in HR+, HER2- Breast Cancer at the EDSA Shangri-La Hotel in response to the alarming trend of breast cancer being the most common type of cancer in the country, and to formally launch a new treatment option for breast cancer: Abemaciclib (Yulareb®).

In the year 2020, 27,163 new cases of breast cancer were diagnosed in the Philippines and breast cancer accounted for 17.7% of all cancer cases, making it the most common type of cancer in the country.¹

On April 15, 2023, ZP Therapeutics held a scientific symposium entitled Taking Hope Further in HR+, HER2- Breast Cancer at the EDSA Shangri-La Hotel in response to this alarming trend, and to formally launch a new treatment option for breast cancer: Abemaciclib (Yulareb®). The event gathered over 100 industry experts and oncologists from across the country.

On April 15, 2023, ZP Therapeutics held a scientific symposium entitled Taking Hope Further in HR+, HER2- Breast Cancer at the EDSA Shangri-La Hotel in response to the alarming trend of breast cancer being the most common type of cancer in the country, and to formally launch a new treatment option for breast cancer: Abemaciclib (Yulareb®).

PNH carries a high disease burden despite treatment

Paroxysmal nocturnal haemoglobinuria (PNH) carries a substantial disease burden and healthcare resource utilization, even in patients already receiving treatment with C5 inhibitors, according to an expert who presented at EHA 2023.

PNH carries a high disease burden despite treatment

Tranexamic acid use before CS reduces blood loss

The use of prophylactic tranexamic acid (TXA) prior to elective Caesarean section (CS) led to significantly lower blood loss in women, particularly those at high risk for postpartum haemorrhage (PPH), according to a study presented at RCOG 2023.

Tranexamic acid use before CS reduces blood loss

OSA treatment with positive airway pressure reduces economic burden in HFpEF

In patients with heart failure with preserved ejection fraction (HFpEF) and comorbid obstructive sleep apnoea (OSA), positive airway pressure (PAP) therapy helps lower the use of healthcare resource, according to a study.

OSA treatment with positive airway pressure reduces economic burden in HFpEF

QUIWI: FLT3 type II inhibitor confers survival advantage in acute myeloid leukaemia

13 Jul 2023 by

The FLT3 type II inhibitor quizartinib, when combined with induction and consolidated therapy and continued for up to 12 cycles, yields survival benefits such as prolonged overall and relapse-free survival in patients with newly diagnosed wild-type acute myeloid leukaemia (AML), as shown in the interim results of the phase II study QUIWI.

QUIWI: FLT3 type II inhibitor confers survival advantage in acute myeloid leukaemia

Does acute kidney injury lead to CKD progression?

Mild to moderate acute kidney injury (AKI) is slightly associated with worsening subsequent kidney function in patients with chronic kidney disease (CKD) following adjustments for pre-AKI estimated glomerular filtration rate (eGFR), proteinuria, and other covariables, with the possibility of no correlation, suggests a study.

Does acute kidney injury lead to CKD progression?